| Literature DB >> 34017690 |
Jeroen Meulemans1,2, Sara Narimani1,2, Esther Hauben3,4, Sandra Nuyts5,6, Annouschka Laenen7, Pierre Delaere1, Vincent Vander Poorten1,2.
Abstract
BACKGROUND/Entities:
Keywords: glottic cancer; laryngeal cancer; margins; oncological outcomes; transoral laser microsurgery
Year: 2021 PMID: 34017690 PMCID: PMC8130557 DOI: 10.3389/fonc.2021.685255
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Overview of patient and tumor characteristics.
| Variable | Value | Proportion (%) |
|---|---|---|
|
| ||
| Mean | 69.02 | |
| SD | 10.972 | |
|
| ||
| Male | 86/96 | 88.58 |
| Female | 10/96 | 10.42 |
|
| ||
| No | 10/93 | 10.75 |
| Past smoker | 62/93 | 66.67 |
| Active smoker | 21/93 | 22.58 |
|
| ||
| Mean | 38.42 | |
| SD | 20.685 | |
|
| ||
| No | 22/90 | 24.44 |
| Yes | 68/90 | 75.56 |
|
| ||
| Mean | 14.11 | |
| SD | 19.225 | |
|
| ||
| T1a | 62/96 | 64.58 |
| T1b | 13/96 | 13.54 |
| T2 | 20/96 | 20.83 |
| T3 | 1/96 | 1.04 |
|
| ||
| N0 | 96/96 | 100.00 |
|
| ||
| Tis | 36/96 | 37.50 |
| T1a | 37/96 | 38.54 |
| T1b | 5/96 | 5.21 |
| T2 | 16/96 | 16.67 |
| T3 | 2/96 | 2.08 |
|
| ||
| No | 58/96 | 60.42 |
| Yes | 38/96 | 39.58 |
|
| ||
| No | 80/96 | 83.33 |
| Yes | 16/96 | 16.67 |
|
| ||
| No | 87/96 | 90.63 |
| Yes | 9/96 | 9.38 |
IQR, interquartile range.
Overview of treatment characteristics.
| Variable | Value | Proportion (%) |
|---|---|---|
|
| ||
| Primary TLM | 87/96 | 90.63 |
| Salvage TLM for recurrence after RT | 9/96 | 9.38 |
|
| ||
| RT | 8/9 | 88.89 |
| Radiochemotherapy | 1/9 | 11.11 |
|
| ||
| Type I | 21/96 | 21.88 |
| Type II | 24/96 | 25.00 |
| Type III | 28/96 | 29.17 |
| Type Va | 15/96 | 15.63 |
| Type Vb | 3/96 | 3.13 |
| Type Vd | 2/96 | 2.08 |
| Type VI | 3/96 | 3.13 |
|
| ||
| Bleeding | 1/9 | 11.11 |
| Dysphagia | 1/9 | 11.11 |
| Aspiration | 4/9 | 44.44 |
| Chondronecrosis | 3/9 | 33.33 |
|
| ||
| Mean | 1.66 | |
| SD | 1.999 | |
| Median | 1.00 | |
| IQR | 1.00;2.00 | |
| Range | 1.00–18.00 | |
|
| ||
| No | 78/96 | 81.25 |
| Yes | 18/96 | 18.75 |
|
| ||
| No residual malignancy | 12/18 | 66.67 |
| Dysplasia | 1/18 | 5.56 |
| Invasive SCC | 5/18 | 27.78 |
|
| ||
| No | 93/96 | 96.88 |
| Yes | 3/96 | 3.13 |
Estimates for OS, DSS, DFS, LRFS, ULC with TLM alone and laryngeal preservation rate.
| Variable | Survival estimates % (95% CI) |
|---|---|
|
| |
| 24 months | 88.47 (77.97–94.15) |
| 48 months | 86.20 (74.65–92.74) |
|
| |
| 24 months | 97.01 (90.73–99.44) |
| 48 months | 94.75 (86.58–98.67) |
|
| |
| 24 months | 86.24 (77.06–93.08) |
| 48 months | 82.22 (70.22–91.48) |
|
| |
| 24 months | 87.58 (78.64–94.03) |
| 48 months | 83.62 (71.75–92.48) |
|
| |
| 24 months | 92.47 (85.19–96.98) |
| 48 months | 88.38 (76.86–95.78) |
|
| |
| 24 months | 93.29 (85.96–97.57) |
| 48 months | 93.29 (85.96–97.57) |
Figure 1Kaplan-Meier curves illustrating LRFS with TLM alone vs LRFS with TLM + adjuvant RT. Subjects who received adjuvant RT showed significantly poorer LRFS when compared to subjects treated with TLM alone (HR 15.974, p = 0.001).
Overview of significant prognosticators for various oncological outcomes after TLM, as identified at univariable and multivariable analyses.
| Variable | Univariable identification of prognostic value of variable for oncological outcomes | Multivariable confirmation of prognostic value of variable for oncological outcomes |
|---|---|---|
|
|
| |
|
| ||
|
| ||
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
| ||
|
|
|
|
|
|
| |
|
| ||
|
| ||
|
|
|
*cT and pT were analyzed as ordinal variables. Indicated HR is related to increase of cT and pT with one level.
OS, overall survival; DSS, disease specific survival; DFS, disease free survival; LRFS, local relapse/recurrence free survival; SCC, squamous cell carcinoma.
Overview of matching variables for current and historical cohort: patient, tumor and treatment characteristics.
| Variables | Current (n = 79) | Historical (n = 79) |
|---|---|---|
|
| ||
| Mean | 68.57 | 67.80 |
| SD | 11.822 | 12.100 |
| Range | (27.96; 94.04) | (35.36; 89.55) |
|
| ||
| Male | 71/79 (89.87%) | 71/79 (89.87%) |
| Female | 8/79 (10.13%) | 8/79 (10.13%) |
|
| ||
| Primary TLM | 70/79 (88.61%) | 68/79 (86.08%) |
| Salvage TLM | 09/79 (11.39%) | 11/79 (13.92%) |
|
| ||
| T1a | 51/79 (64.56%) | 52/79 (65.82%) |
| T1b | 9/79 (11.39%) | 7/79 (8.86%) |
| T2 | 18/79 (22.78%) | 19/79 (24.05%) |
| T3 | 1/79 (1.27%) | 1/79 (1.27%) |
|
| ||
| Stage 0 | 21/79 (26.58%) | 10/79 (12.66%) |
| Stage I | 41/79 (51.90%) | 57/79 (72.15%) |
| Stage II | 15/79 (18.99%) | 11/79 (13.92%) |
| Stage III | 2/79 (2.53%) | 1/79 (1.27%) |
|
| ||
| No | 76/79 (96.20%) | 75/79 (94.94%) |
| Yes | 3/79 (3.80%) | 4/79 (5.06%) |
|
| ||
| Invasive SCC | 58/79 (73.42%) | 57/79 (72.15%) |
| CIS | 21/79 (26.58%) | 22/79 (27.85%) |
|
| ||
| Type I | 13/79 (16.46%) | 14/79 (17.72%) |
| Type II | 19/79 (24.05%) | 15/79 (18.99%) |
| Type III | 27/79 (34.18%) | 30/79 (37.97%) |
| Type IV | 0/79 (0.00%) | 2/79 (2.53%) |
| Type Va | 13/79 (16.46%) | 8/79 (10.13%) |
| Type Vb | 3/79 (3.80%) | 1/79 (1.27%) |
| Type Vc | 0/79 (0.00%) | 3/79 (3.80%) |
| Type Vd | 2/79 (2.53%) | 1/79 (1.27%) |
| Type VI | 2/79 (2.53%) | 5/79 (6.33%) |